Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / ADR
-
Shares outstanding
-
55.6M
-
Number of holders
-
155
-
Total 13F shares, excl. options
-
60.3M
-
Shares change
-
-803K
-
Total reported value, excl. options
-
$5.64B
-
Value change
-
-$73.7M
-
Put/Call ratio
-
1.12
-
Number of buys
-
69
-
Number of sells
-
-75
-
Price
-
$93.64
Significant Holders of Ascendis Pharma A/S - ADR (ASND) as of Q3 2023
190 filings reported holding ASND - Ascendis Pharma A/S - ADR as of Q3 2023.
Ascendis Pharma A/S - ADR (ASND) has 155 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 60.3M shares
.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (10.7M shares), Artisan Partners Limited Partnership (6M shares), FMR LLC (5.14M shares), T. Rowe Price Investment Management, Inc. (3.98M shares), JANUS HENDERSON GROUP PLC (3.85M shares), WESTFIELD CAPITAL MANAGEMENT CO LP (3.8M shares), Avoro Capital Advisors LLC (3.67M shares), WELLINGTON MANAGEMENT GROUP LLP (3.28M shares), Capital International Investors (2.17M shares), and PRICE T ROWE ASSOCIATES INC /MD/ (1.64M shares).
This table shows the top 155 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.